

## Curriculum Vitae

Photo	<b>Name</b> <small>(First Name, Middle Name Last Name)</small>	Jun Miyoshi
	<b>Position</b>	Associate Professor
	<b>Affiliation</b>	Department of Gastroenterology and Hepatology, Kyorin University School of Medicine
	<b>Country</b>	Japan
	<b>Major Field</b>	Gastroenterology, Microbiome medicine

### Education Background

2000-2006: Keio University School of Medicine (Tokyo, Japan); M.D.  
 2008-2012: Graduate School of Medicine, Keio University (Tokyo, Japan); Ph.D.

### Professional Experience

2006-2008: Residency, Kawasaki Municipal Hospital (Kanagawa, Japan)  
 2008-2012: Clinical Fellow (M.D., Ph.D. Program), Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University Hospital (Tokyo, Japan)  
 2012-2014: Clinical instructor, Department of Gastroenterology and Hepatology, Tokyo Dental College Ichikawa General Hospital (Chiba, Japan)  
 2014-2019: Postdoctoral Scholar, Section of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, the University of Chicago (IL, U.S.A.)  
 2019-2022: Senior Assistant Professor, Department of Gastroenterology and Hepatology, Kyorin University School of Medicine  
 2022-present: Associate Professor, Department of Gastroenterology and Hepatology, Kyorin University School of Medicine

### Professional Organizations

- Japanese Society of Internal Medicine (Board certified)
- Japanese Society of Gastroenterology (Board certified)
- Japanese Gastroenterological Endoscopy Society (Board certified)
- The Japanese Society for Mucosal Immunology (Councilor)
- Japanese Society of Inflammatory Bowel Disease
- Asian Organization for Crohn's and Colitis
- European Crohn's and Colitis Organisation
- International Bowel Ultrasound Group



American Gastroenterological Association  
Japan Society of Coloproctology  
Japanese Society of Medical Oncology  
The Japanese Gastroenterological Association  
The Japanese Society of Clinical Immunology

### Scientific Publication

- 1 **Miyoshi J**, Ozaki R, Yonezawa H, Mori H, Kawamura N, Matsuura M, Hisamatsu T. Ratio of submucosal thickness to total bowel wall thickness as a new sonographic parameter to estimate endoscopic remission of ulcerative colitis. *J Gastroenterol.* 2022;57(2):82-89.
- 2 **Miyoshi J**, Matsuura M, Hisamatsu T. Safety evaluation of ustekinumab for moderate-to-severe ulcerative colitis. *Expert Opin Drug Saf.* 2022;21(1):1-8.
- 3 Miura M, Shimizu H, Saito D, **Miyoshi J**, Matsuura M, Kudo T, Hirayama D, Yoshida M, Arai K, Iwama I, Nakase H, Shimizu T, Hisamatsu T. Multicenter, cross-sectional, observational study on Epstein-Barr viral infection status and thiopurine use by age group in patients with inflammatory bowel disease in Japan (EBISU study). *J Gastroenterol.* 2021;56(12):1080-1091.
- 4 **Miyoshi J**, Miyoshi S, Delmont TO, Cham C, Lee STM, Sakatani A, Yang K, Shan Y, Kennedy M, Kiefl E, Yousef M, Crosson S, Sogin M, Antonopoulos DA, Eren AM, Leone V, Chang EB. Early-Life Microbial Restitution Reduces Colitis Risk Promoted by Antibiotic-Induced Gut Dysbiosis in Interleukin 10<sup>-/-</sup> Mice. *Gastroenterology.* 2021;161(3):940-952.e15.
- 5 **Miyoshi J**, Lee STM, Kennedy M, Puertolas M, Frith M, Koval JC, Miyoshi S, Antonopoulos DA, Leone V, Chang EB. Metagenomic Alterations in Gut Microbiota Precede and Predict Onset of Colitis in the IL10 Gene-Deficient Murine Model. *Cell Mol Gastroenterol Hepatol.* 2021;11(2):491-502.
- 6 Sakuraba A, Nemoto N, Hibi N, Ozaki R, Tokunaga S, Kikuchi O, Minowa S, Mitsui T, Miura M, Saito D, Hayashida M, **Miyoshi J**, Matsuura M, Yoneyama M, Ohnishi H, Hisamatsu T. Extent of disease affects the usefulness of fecal biomarkers in ulcerative colitis. *BMC Gastroenterol.* 2021;21(1):197.
- 7 Watanabe S, **Miyoshi J\***, Toki M, Kambayashi K, Kitada S, Nosaka T, Goto T, Ota H, Ochiai K, Gondo K, Ikeuchi N, Tsuji S, Nakamura K, Shibahara J, Hisamatsu T. Effectiveness of introducing a 20-gauge core biopsy needle with a core trap in EUS-FNA/B for diagnosing pancreatic cancer. *BMC Gastroenterol.* 2021;21(1):8. \*co-corresponding author
- 8 **Miyoshi J**, Maeda T, Matsuoka K, Saito D, Miyoshi S, Matsuura M, Okamoto S, Tamura S, Hisamatsu T. Machine learning using clinical data at baseline predicts the efficacy of vedolizumab at week 22 in patients with ulcerative colitis. *Sci Rep.* 2021;11(1):16440.
- 9 Saito D, Matsuura M, Ozaki R, Tokunaga S, Minowa S, Mitsui T, Miura M, Sakuraba A, Hayashida M, **Miyoshi J**, Hisamatsu T. Clinical response of vedolizumab at week 6 predicted endoscopic remission at week 24 in ulcerative colitis. *JGH Open.* 2021;5(9):1056-1062.
- 10 **Miyoshi J**, Hisamatsu T. The impact of maternal exposure to antibiotics on the development of child gut microbiome. *Immunol Med.* 2021. doi: 10.1080/25785826.2021.1963189. Epub ahead of print.
- 11 **Miyoshi J**, Rao MC, Chang EB. Navigating the Human Gut Microbiome: Pathway to Success from Lessons Learned. *Gastroenterology.* 2020;159(6):2019-2024.
- 12 Ohno A, **Miyoshi J**, Tanabe H, Kusuhara M, Toki M, Chiba T, Shimoyamada H, Shibahara J, Hisamatsu T. Gastropathy associated with lanthanum phosphate deposition that was endoscopically tracked for 3 years.

A case report. BMC Gastroenterol. 2020;20(1):292.

- 13 **Miyoshi J**, Saito D, Nakamura M, Miura M, Mitsui T, Kudo T, Murakami S, Matsuura M, Hisamatsu T. Half-Elemental Diet Shifts the Human Intestinal Bacterial Compositions and Metabolites: A Pilot Study with Healthy Individuals. Gastroenterol Res Pract. 2020;2020:7086939.
- 14 Ohno A, **Miyoshi J\***, Kato A, Miyamoto N, Yatagai T, Hada Y, Kusuhaara M, Jimbo Y, Ida Y, Tokunaga K, Okamoto S, Hisamatsu T. Endoscopic severe mucosal atrophy indicates the presence of gastric cancer after Helicobacter pylori eradication -analysis based on the Kyoto classification. BMC Gastroenterol. 2020;20(1):232. \*co-corresponding author
- 15 Kikuchi O, Saito D, Miura M, Wada H, Ozaki R, Tokunaga S, Minowa S, Fukuyama M, Mitsui T, Sakuraba A, Hayashida M, **Miyoshi J**, Matsuura M, Ohyama M, Hisamatsu T. Two cases in which tofacitinib effectively treated both ulcerative colitis and alopecia areata. Clin J Gastroenterol. 2020;13(5):788-793.
- 16 Basson AR, LaSalla A, Lam G, Kulpins D, Moen EL, Sundrud MS, **Miyoshi J**, Ilic S, Theriault BR, Cominelli F, Rodriguez-Palacios A. Artificial microbiome heterogeneity spurs six practical action themes and examples to increase study power-driven reproducibility. Sci Rep. 2020;10(1):5039.
- 17 Hayashida M, **Miyoshi J\***, Mitsui T, Miura M, Saito D, Sakuraba A, Kawashima S, Ikegaya N, Fukuoka K, Karube M, Komagata Y, Kaname S, Okada AA, Fujimori S, Matsuura M, Hisamatsu T. Elevated fecal calprotectin and lactoferrin associated with small intestinal lesions in patients With Behçet disease. J Gastroenterol Hepatol. 2020; 35(8):1340-1346. \*co-corresponding author
- 18 Saito D, Hibi N, Ozaki R, Kikuchi O, Sato T, Tokunaga S, Minowa S, Ikezaki O, Mitsui T, Miura M, Sakuraba A, Hayashida M, **Miyoshi J**, Matsuura M, Nakase H, Hisamatsu T. MEFV gene-related enterocolitis account for some cases diagnosed as inflammatory bowel disease unclassified. Digestion. 2020;101(6):785-793.
- 19 **Miyoshi J**, Sofia MA, Pierre JF. The evidence for fungus in Crohn's disease pathogenesis. Clin J Gastroenterol. 2018;11(6):449-456.
- 20 **Miyoshi J**, Matsuoka K, Yoshida A, Naganuma M, Hisamatsu T, Yajima T, Inoue N, Okamoto S, Iwao Y, Ogata H, Ueno F, Hibi T, Kanai T. 5-aminosalicylic acid aggravates colitis mimicking exacerbation of ulcerative colitis. Intest Res. 2018;16(4):635-640.
- 21 **Miyoshi J**, Leone V, Nobutani K, Musch MW, Martinez-Guryn K, Wang Y, Miyoshi S, Bobe AM, Eren AM, Chang EB. Minimizing confounders and increasing data quality in murine models for studies of the gut microbiome. PeerJ. 2018;6:e5166.
- 22 Martinez-Guryn K, Hubert N, Frazier K, Urlass S, Musch MW, Ojeda P, Pierre JF, **Miyoshi J**, Sontag TJ, Cham CM, Reardon CA, Leone V, Chang EB. Small intestine microbiota regulate host digestive and absorptive adaptive responses to dietary lipids. Cell Host Microbe. 2018;23(4):458-469.e5.
- 23 Pierre JF, Hinterleitner R, Bouziat R, Hubert NA, Leone V, **Miyoshi J**, Jabri B, Chang EB. Dietary antioxidant micronutrients alter mucosal inflammatory risk in a murine model of genetic and microbial susceptibility. J Nutr Biochem. 2018;54:95-104.
- 24 **Miyoshi J**, Qiao Y, Chang EB. The role of the intestinal microbiota in the pathogenesis and treatment of inflammatory bowel diseases. Semin Colon Rectal Surg. 2018;29:21-27.
- 25 **Miyoshi J**, Nobutani K, Musch MW, Ringus DL, Hubert NA, Yamamoto M, Kase Y, Nishiyama M, Chang EB. Time-, Sex-, and Dose-Dependent Alterations of the Gut Microbiota by Consumption of Dietary Daikenchuto (TU-100). Evid Based Complement Alternat Med. 2018;2018:7415975.
- 26 Nobutani K, **Miyoshi J**, Musch MW, Nishiyama M, Watanabe J, Kaneko A, Yamamoto M, Yoshida M, Kono T, Jeong H, Chang EB. Daikenchuto (TU-100) alters murine hepatic and intestinal drug metabolizing

- enzymes in an in vivo dietary model: effects of gender and withdrawal. *Pharmacol Res Perspect.* 2017;5(5):e00361.
- 27 **Miyoshi J**, Bobe AM, Miyoshi S, Huang Y, Hubert N, Delmont TO, Eren AM, Leone V, Chang, EB. Peripartum exposure to antibiotics promotes persistent gut dysbiosis, immune imbalance, and inflammatory bowel disease in genetically prone offspring. *Cell Rep.* 2017;20(2):491-504.
- 28 Hasebe T, Matsukawa J, Ringus D, **Miyoshi J**, Hart J, Kaneko A, Yamamoto M, Kono T, Fujiya M, Kohgo Y, Wang CZ, Yuan CS, Bissonnette M, Musch MW, Chang EB. Daikenchuto (TU-100) suppresses tumor development in the azoxymethane and APCmin/+ mouse models of experimental colon cancer. *Phyther Res.* 2017;31(1):90-99.
- 29 **Miyoshi J**, Chang EB. The gut microbiota and inflammatory bowel diseases. *Transl Res.* 2017; 179: 38-48.
- 30 **Miyoshi J**, Hisamatsu T, Matsuoka K, Naganuma M, Maruyama Y, Yoneno K, Mori K, Kiyohara H, Nanki K, Okamoto S, Yajima T, Iwao Y, Ogata H, Hibi T, Kanai T. Early intervention with adalimumab may contribute to favorable clinical efficacy in patients with Crohn's disease. *Digestion.* 2014;90(2):130-6.
- 31 Yoneno K, Hisamatsu T, Matsuoka K, Okamoto S, Takayama T, Ichikawa R, Sujino T, **Miyoshi J**, Takabayashi K, Mikami Y, Mizuno S, Wada Y, Yajima T, Naganuma M, Inoue N, Iwao Y, Ogata H, Hasegawa H, Kitagawa Y, Hibi T, Kanai T. Risk and management of intra-abdominal abscess in Crohn's disease treated with infliximab. *Digestion.* 2014;89(3):201-8.
- 32 Kishikawa H, Kaida S, Takarabe S, **Miyoshi J**, Matsukubo T, Miyauchi J, Tanaka Y, Miura S, Nishida J. Fundic gland polyps accurately predict a low risk of future gastric carcinogenesis. *Clin Res Hepatol Gastroenterol.* 2014;38(4):505-12.
- 33 **Miyoshi J**, Matsuoka K, Inoue N, Hisamatsu T, Ichikawa R, Yajima T, Okamoto S, Naganuma M, Sato T, Kanai T, Ogata H, Iwao Y, Hibi T. Mucosal healing with oral tacrolimus is associated with favorable medium- and long-term prognosis in steroid-refractory/dependent ulcerative colitis patients. *J Crohns Colitis.* 2013;7(12):e609-14.
- 34 Kishikawa H, Nishida J, Takarabe S, Arahata K, Ito A, **Miyoshi J**, Kaida S, Hibi T. "Circular reddish lesions": a possibly characteristic endoscopic finding in Henoch-Schönlein purpura. *Endoscopy.* 2013;45(S02):E33-E34.
- 35 Uo M, Hisamatsu T, **Miyoshi J**, Kaito D, Yoneno K, Kitazume MT, Mori M, Sugita A, Koganei K, Matsuoka K, Kanai T, Hibi T. Mucosal CXCR4+ IgG plasma cells contribute to the pathogenesis of human ulcerative colitis through Fc  $\gamma$  R-mediated CD14 macrophage activation. *Gut.* 2013;62(12):1734-44.
- 36 Nakamura Y, Kanai T, Saeki K, Takabe M, Irie J, **Miyoshi J**, Mikami Y, Teratani T, Suzuki T, Miyata N, Hisamatsu T, Nakamoto N, Yamagishi Y, Higuchi H, Ebinuma H, Hozawa S, Saito H, Itoh H, Hibi T. CCR2 knockout exacerbates cerulein-induced chronic pancreatitis with hyperglycemia via decreased GLP-1 receptor expression and insulin secretion. *Am J Physiol Gastrointest Liver Physiol.* 2013;304(8):G700-7.
- 37 **Miyoshi J**, Yajima T, Shimamura K, Matsuoka K, Okamoto S, Higuchi H, Funakoshi S, Takaishi H, Hibi T. 5-aminosalicylic acid mediates expression of cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase to suppress colorectal tumorigenesis. *Anticancer Res.* 2012;32(4):1193-202.
- 39 Inoue N, Iwao Y, Matsuoka K, **Miyoshi J**, Mikami Y, Sujino T, Hisamatsu T, Okamoto S, Kanai T, Hibi T, Ogata H. The effect of anti-TNF- $\alpha$  antibody in refractory ulcerative colitis. *Stomach and Intestine (Tokyo)* 2011;46(13):1981-91.
- 40 **Miyoshi J**, Yajima T, Okamoto S, Matsuoka K, Inoue, N, Hisamatsu T, Shimamura K, Nakazawa A, Kanai T, Ogata H, Iwao Y, Mukai M, Hibi T. Ectopic expression of blood type antigens in inflamed mucosa with higher

incidence of FUT2 secretor status in colonic Crohn's disease. J Gastroenterol. 2011;46(9):1056-63.

### Honors & Awards

2022	Award for Outstanding Reviewers of Internal Medicine
2021	The 10th Kyorin Medical Society Research Award
2021	Japan Digestive Disease Week (JDDW) 2021 Young Investigator Award
2019	The 10th Annual Meeting of Japanese Society for Inflammatory Bowel Disease Outstanding Poster Presentation Award
2019	The 56th Annual Meeting of the Japan Society for Mucosal Immunology Young Researcher's Award
2019	Crohn's & Colitis Congress 2019 Young Investigator Travel Award The Crohn's & Colitis Foundation and the American Gastroenterological Association
2011	Japanese Society of Inflammatory Bowel Disease Travel Award for CCFA 2011
2008-2011	Keio University Graduate School Scholarship
2000-2006	Keio University School of Medicine Scholarship